
Opinion|Videos|November 4, 2024
Perceptions on the Future of Bispecific Therapies for NHL
Panelists discuss their perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.
Advertisement
Video content above is prompted by the following:
- What do you perceive the future to look like for patients being treated with bispecific antibodies for non-Hodgkin lymphoma?
- What remain the key unmet needs?
Do you have any clinical pearls for the community oncologist?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5





































